Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy

NCT06470880 is registered in ClinicalTrials.gov with The Christie NHS Foundation Trust as lead sponsor.

NCT NCT06470880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06470880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy
Lead sponsor
The Christie NHS Foundation Trust
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2024
Completion date
June 30, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma